Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  RedHill Biopharma Ltd    RDHL   IL0011223810

REDHILL BIOPHARMA LTD

(RDHL)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed Tel Aviv Stock Exchange
02/10/2019 02/11/2019 02/12/2019 02/13/2019 02/14/2019 Date
317.4(c) 314.1(c) 319.4(c) 320(c) 308(c) Last
346 467 281 501 141 162 262 693 305 671 Volume
-0.81% -1.04% +1.69% +0.19% -3.75% Change
More quotes
Financials (USD)
Sales 2018 9,75 M
EBIT 2018 -39,4 M
Net income 2018 -40,5 M
Finance 2018 28,2 M
Yield 2018 -
Sales 2019 13,2 M
EBIT 2019 -39,1 M
Net income 2019 -39,1 M
Debt 2019 12,1 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 21,7x
EV / Sales2019 19,1x
Capitalization 240 M
More Financials
Company
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It... 
More about the company
Surperformance© ratings of RedHill Biopharma Ltd
Trading Rating : - Investor Rating :
More Ratings
Latest news on REDHILL BIOPHARMA LTD
01/18REDHILL BIOPHARMA : Announces Fifth U.S. Patent Covering TALICIA for H. pylori I..
AQ
01/18REDHILL BIOPHARMA : Announces Fifth U.S. Patent Covering TALICIA for H. pylori I..
AQ
01/18REDHILL BIOPHARMA : Announces Fifth U.S. Patent Covering TALICIA for H. pylori I..
AQ
01/17RedHill Biopharma Announces Fifth U.S. Patent Covering TALICIA® for H. pylori..
GL
2018RedHill Biopharma Announces Closing of $20 Million Underwritten Offering
GL
2018RedHill Biopharma Announces Pricing of $20 Million Underwritten Offering
GL
2018RedHill Biopharma Announces Proposed Public Offering of its American Deposita..
GL
2018REDHILL BIOPHARMA : Announces Positive Top-Line Results from Confirmatory Phase ..
AQ
2018REDHILL BIOPHARMA : Announces Positive Top-Line Results from Confirmatory Phase ..
AQ
2018REDHILL BIOPHARMA : Israel's RedHill says drug shown effective in eradicating gu..
AQ
More news
Sector news : Bio Therapeutic Drugs
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06Eli Lilly Cuts Earnings Forecast on Pending Loxo Acquisition
DJ
More sector news : Bio Therapeutic Drugs
Chart REDHILL BIOPHARMA LTD
Duration : Period :
RedHill Biopharma Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REDHILL BIOPHARMA LTD
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
EPS Revisions
Managers
NameTitle
Dror Ben-Asher Chairman & Chief Executive Officer
Gilead Raday Chief Operating Officer
Micha Ben-Chorin Chief Financial Officer
Reza Fathi Senior Vice President-Research & Development
Ira N. Kalfus Medical Director
Sector and Competitors
1st jan.Capitalization (M$)
REDHILL BIOPHARMA LTD52.70%240
GILEAD SCIENCES6.11%85 858
VERTEX PHARMACEUTICALS12.08%47 462
REGENERON PHARMACEUTICALS9.37%44 554
GENMAB-5.76%9 362
SAREPTA THERAPEUTICS INC26.87%9 013